AOD-9604 in Australia: a growth-hormone-fragment research guide

AOD-9604 in Australia. AOD-9604 is a synthetic peptide studied in laboratory research as a modified fragment of the C-terminal lipolytic domain of human growth hormone — the hGH(177-191) sequence with an added N-terminal tyrosine. This guide is a research-reference summary for Australian researchers, framed strictly around lipid-metabolism-pathway research. It makes no fat-loss, weight-loss, body-composition, or human-use claim.

What AOD-9604 is

AOD-9604 is a 16-residue synthetic peptide — the sequence Tyr-hGH(177-191). It corresponds to the C-terminal lipolytic fragment of the human growth-hormone molecule, with an added N-terminal tyrosine; an intramolecular disulfide bridge between its two cysteine residues forms a small loop that mirrors the native hGH C-terminal loop. It is a distinct research entity from the intact 191-residue hormone — a defined synthetic fragment rather than the whole molecule.

The lipid-metabolism pathway it probes

In receptor and pathway research, AOD-9604 is studied as a probe of the growth-hormone lipolytic pathway that is structurally separable from the somatogenic, IGF-1-mediated actions of the intact hormone. The original metabolic characterisation of the synthetic fragment was reported by Ng and colleagues (Hormone Research, 2000); Heffernan and colleagues (Endocrinology, 2001) used β3-adrenergic-receptor knock-out models to probe the pathway implicated in the fragment’s lipid-metabolic signalling — the reason the β3-adrenergic receptor is referenced across AOD-9604 research literature. It is studied in vitro as a research tool, not as a treatment.

A defined fragment makes a convenient reference compound

Because the peptide is a defined synthetic fragment, it is also studied as an analytical reference: Cox and colleagues (Drug Testing and Analysis, 2015) characterised its detection and in-vitro metabolic breakdown products. As a short, defined sequence it reconstitutes and stores predictably, which is why it is used to study the lipid-metabolic signal in isolation from the hormone’s receptor-mediated growth axis, rather than as a probe of the intact hormone.

Not a fat-loss compound — the framing matters

AOD-9604 is framed here strictly around lipid-metabolism-pathway research in controlled laboratory models. Elite AU Peptides makes no fat-loss, weight-loss, body-composition, or human-use claim about this product. It sits in the GLP-class & metabolic research category alongside retatrutide and tesamorelin; the GLP-1 research peptides pillar covers the wider metabolic-research context.

Identity, purity and compliance

Every batch of AOD-9604 is independently HPLC-tested by Janoshik before it is listed, with the certificate published on the product page and in the lab-reports library — real batch number, measured percentage, independently verifiable at janoshik.com. AOD-9604 is not TGA-approved and is not a therapeutic good; it is supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption. Researchers should consult primary peer-reviewed sources for pathway data and protocol-specific reference values.